Fundación MEDINA is part of the NOVA-VRE consortium, an R&D project aimed at developing new therapies based on enzybiotics to combat infections caused by vancomycin-resistant Enterococcus faecium, one of the most problematic bacteria in hospital settings due to its high resistance to conventional antibiotic treatments.
A leading consortium in biotechnology and biomedicine
NOVA-VRE is coordinated by Telum Therapeutics S.L., a biotechnology company specialised in the development of enzybiotics, and involves the participation of the CSIC’s ‘Blas Cabrera’ Institute of Physical Chemistry, the Seville Institute of Biomedicine and Fundación MEDINA.
A commitment to overcoming the limitations of current antibiotics
NOVA-VRE is focused on the design of natural and chimeric enzymes optimised using machine learning, with the aim of developing a specific, effective and safe therapeutic solution. MEDINA’s participation will contribute to the development of the analytical capabilities needed to advance the validation of these new therapies.
The expected impact of the project extends beyond the clinical sphere: NOVA-VRE aims to reduce antimicrobial resistance, drive innovation in the Spanish biotechnology sector and strengthen collaboration between public and private research.
Project CPP2024-011351 funded by MICIU/AEI/10.13039/501100011033/ and by the ERDF, EU.
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
Many repetitive regions of the genome have been considered “junk DNA...
